Medline MDLN

Reference table

Three facts stop it being buyable here. First, gross margin is compressing sharply: 24.8% in the March 2025 quarter to 22.6% in March 2026 — 220 basis points on a business with a 5.7% operating margin, and GAAP net income for that quarter fell 60% year-over-year ($129M against $322M) on 10.7% more revenue, even as the adjusted figure beat. Second, a ten-percent holder sold 21,969,126 shares at $36.5375 on 2026-05-28 — roughly $803M, at a price 9.7% below today's — and retains approximately 99.8 million shares, about 12% of the count. Third, the file is unusually opaque: seg_prod and seg_geo are both entirely empty for a $29B business, there is no 200-day moving average and no twelve-month return, and the reported beta of −0.41 is a short-history artifact. Base case $41 against a $40.47 spot, with earnings tomorrow. Watch.

1. Data integrity — what we rejected, and what is simply missing

REJECTED — the FY2025 annual EBITDA figure

inc_a for FY2025 reports ebitda: 1,952,000,000 against operatingIncome: 2,212,000,000. EBITDA cannot be below operating income — depreciation and amortisation are added, not subtracted. Two further checks confirm the corruption:

• The quarterly EBITDA figures for FY25 sum to $2,849M ($799M + $842M + $826M + $382M), not $1,952M.
• FY2024 reported EBITDA of $3,532M on lower revenue and near-identical operating income ($2,225M). A fall to $1,952M would be inexplicable.

We use $2,849M as the FY25 EBITDA reference and label it as the quarterly sum.

REJECTED — the Q4'25 quarterly EBITDA figure

inc_q for 2025-12-31 reports ebitda: 382,000,000 against operatingIncome: 425,000,000 — the same impossibility at quarterly level, and starkly out of line with the surrounding quarters ($799M, $842M, $826M, and $681M in March 2026). Rejected. Note that the $2,849M quarterly sum above therefore itself contains one bad quarter and is likely understated; a cleaner estimate using the March 2026 quarter's $681M in place of the corrupt $382M gives roughly $3,148M, which is exactly the FY26E consensus EBITDA. We use $2,849M conservatively and flag the likely understatement.

REJECTED — the trailing capital-expenditure and free-cash-flow metrics

km_ttm reports capexToRevenueTTM: 0.00017158 (0.017% of revenue) and capexToDepreciationTTM: 0.0075 — implying trailing capital expenditure of roughly $5M against $447M actually reported in FY25 and $364M in FY24. The trailing capex field is corrupt, and the consequence is that priceToFreeCashFlowRatioTTM (22.4x), freeCashFlowYieldTTM (4.46%), freeCashFlowPerShareTTM ($1.862) and evToFreeCashFlowTTM (29.3x) are ALL OVERSTATED and are discarded.

Our recomputation from cf_a FY25: operating cash flow $1,744M less capital expenditure $447M = free cash flow $1,297M, a 3.79% free-cash-flow yield on the $34.22B market capitalisation — not the 4.46% the vendor reports. Labelled as our computation.

REJECTED — the reported beta

profile.beta reads −0.41062886. A negative beta for a medical-supply distributor is not an economic fact; it is a regression artifact from under eight months of price history since the 2025-12-17 listing. Corroborating evidence of insufficient history: tech.sma200 is null and tech.ret_12m is null. The beta is unusable and no risk statement in this dive relies on it.

FLAGGED — stock-based compensation reported as zero in every year

cf_a reports stockBasedCompensation: 0 for FY22, FY23, FY24 and FY25. For a newly public company with 45,000 employees this is implausible; it is more likely an artifact of the pre-IPO private-company reporting basis. Flagged; it means the reported free cash flow of $1,297M may be flattered by an undisclosed non-cash compensation charge, and we cannot size it.

FLAGGED — the FY2025 equity presentation is not comparable to prior years

bal_a FY2025 shows totalEquity: 19,286M comprising totalStockholdersEquity: 10,737M and minorityInterest: 8,549M. FY2024 and FY2023 both report zero minority interest. The non-controlling interest appears for the first time in FY25, reflecting the IPO reorganisation into what appears to be an Up-C-style structure. FY25 equity is therefore not comparable with FY24, and price-to-book metrics across the transition are meaningless.

FLAGGED — share count inconsistency

inc_q Q1'26 gives 819.0M basic and 825.0M diluted shares. The quote's market capitalisation of $34,221.7M at $40.47 implies 845.6M shares — a 2.5% discrepancy. km_ttm.revenuePerShareTTM of $35.580 against trailing revenue of $29,140M implies 819.0M. We use 825M diluted for per-share arithmetic and flag the spread, noting that with $8,549M of non-controlling interest on the balance sheet the true economic count may be higher than either figure.

SEVERE GAP — seg_prod and seg_geo are both entirely empty

There is no product revenue split and no geographic revenue split for a $29.1 billion-revenue business — not for FY25, not for any year. The profile describes two divisions (Medline Brand and Supply Chain Solutions) and three Medline Brand categories (Frontline Care, Surgical Solutions, and a third), and none of them appear in the data with a revenue figure attached.

This is the most consequential gap in the file. It means we cannot determine whether the gross-margin compression documented in §3 is concentrated in manufactured products or in distribution, whether it is domestic or import-driven, or whether it is mix or price. We flag explicitly that the central operating question in this dive cannot be answered from this data, and no claim below rests on a segment split.

GAP — only four earnings dates exist

earn_cal contains four rows: 2025-11-04 (adjusted EPS $0.31, no estimate recorded), 2026-02-25 ($0.22 against $0.2381, a miss), 2026-05-06 ($0.33 against $0.2952, a beat), and the pending 2026-08-05. There is no meaningful beat history — one miss, one beat, one unmeasurable — and no trailing adjusted-EPS figure can be constructed because the June 2025 quarter has no adjusted number. Where this dive uses "adjusted EPS," it uses only the consensus forward series, never a trailing adjusted multiple.

PASSED — the forecast EBITDA series, and this is worth noting

In contrast with NTRA, ILMN and TWLO in this same batch, Medline's est EBITDA line survives an internal consistency check: FY26E EBITDA of $3,148M sits above FY26E EBIT of $2,001M by $1,146M of implied depreciation and amortisation, both are positive, and the level is close to FY24's actual $3,532M. The FY26-28 EBITDA series is used with confidence and forms the basis of the valuation in §6.

CLEAN — the income statement

FY25 quarterly revenue sums to $28,432M ($6,644M + $6,886M + $7,115M + $7,787M), matching inc_a exactly. Quarterly EPS sums to $1.45 against the stated $1.43 — a rounding difference. inc_q[0] (2026-03-31) is internally consistent: revenue $7,352M, gross profit $1,665M (22.6%), operating income $422M, net income $129M, EPS $0.16 on 825M diluted shares ($129M ÷ 825M = $0.156). Confirmed.

2. The business and the deleveraging engine

Per the profile: a global manufacturer of medical and surgical products serving hospitals, surgical centres, physician practices, post-acute care facilities and nursing homes, organised into Medline Brand (proprietary manufacturing and sourcing — Frontline Care covering wound care, examination gloves, skin and incontinence products, sanitation supplies, textiles, hand sanitiser, durable medical equipment and infection control; Surgical Solutions covering procedure trays, drapes, gowns, personal protective equipment, sterile wraps, instruments and surgeon's gloves) and Supply Chain Solutions (distribution). 45,000 employees. Chief executive James Boyle. Listed 2025-12-17.

The deleveraging, quarter by quarter, is the most important operating fact in this file:

Interest expense fell from $233M (June 2025) to $165M (March 2026) — a 29.2% reduction, or roughly $272M annualised. The balance-sheet cause is visible: net debt fell from $16,649M (FY24) to $10,622M (FY25), a $6,027M reduction, funded by the offering (the cash-flow statement shows $2,003M of "common stock repurchased" in FY25 and a $1,689M net increase in cash — IPO mechanics rather than a buyback in the ordinary sense).

On a business earning $964M of trailing net income, $272M of annualised pre-tax interest saving is roughly 22% of after-tax earnings, arriving mechanically. That is the strongest thing in this file and it is why the verdict is Watch rather than Avoid.

But look at the same table's right-hand columns. Operating income fell from $629M (June 2025) to $422M (March 2026) — down 33% — and net income from $333M to $129M, down 61%, even as interest expense fell $68M. The interest saving is being entirely consumed by operating deterioration, and then some. That is the tension this dive is about.

3. Gross margin — the single most important number

Read the last two rows against the fifth. The March 2026 quarter delivered 22.6% against 24.8% in the same quarter a year earlier — a 220 basis-point decline — and it is the lowest quarterly gross margin in the file. Trailing gross margin of 24.0% is already 240 basis points below the FY25 annual figure of 26.4%.

Why this matters more than it would at most companies: Medline's operating margin is only 7.0% trailing and 5.7% in the March quarter. Gross margin is therefore not a comfort buffer — it is nearly the whole profit pool. 220 basis points on $29.1B of revenue is roughly $640M of gross profit, which exceeds the entire trailing net income of $964M.

What the file cannot tell us, and it is the crucial question: whether this is tariffs and input costs on globally sourced product, competitive price pressure from health-system procurement, or an adverse mix shift toward lower-margin distribution. seg_prod and seg_geo are both empty (§1), so the question is unanswerable from this data. Given that the profile describes a globally sourced physical-product line (gloves, gowns, PPE, textiles), input costs and trade policy are the most plausible candidates — but that is inference and it is labelled as such.

The divergence between GAAP and adjusted results in the March quarter deserves specific attention. GAAP net income fell 60% year-over-year ($129M against $322M) while adjusted EPS beat consensus ($0.33 against $0.2952). Adjusted EPS of $0.33 against GAAP EPS of $0.16 means roughly half the reported adjusted earnings are add-backs, and the file does not disclose their composition. Any investor relying on the adjusted series here is relying on an adjustment equal in size to the reported profit.

4. Balance sheet and leverage

• Net debt / EBITDA: 3.73x on our $2,849M FY25 EBITDA reference, or 3.37x on FY26E consensus EBITDA of $3,148M. km_ttm reports 3.81x. All three point to a business levered between 3.3x and 3.8x — post-buyout territory, materially improved from the roughly 5.8x implied by FY24's $16,649M against $2,849M.
• Interest coverage 2.59x — the lowest in this batch and genuinely thin. Debt service coverage 3.00x.
• Goodwill $8,079M is 21.0% of total assets and 23.6% of market capitalisation. Tangible book value per share is negative $2.98, so the entire equity value rests on intangibles and earnings power.
• Inventory $4,769M with 79.3 days on hand and a 110-day cash conversion cycle. Growth in this business consumes working capital: inventory rose $956M between FY23 and FY25 while revenue rose $5,201M.
• Free cash flow: $1,297M (FY25), $1,405M (FY24), $1,400M (FY23) — our computation (§1). Note carefully: free cash flow is FLAT across three years in which revenue grew 22.4%. That is the working-capital drag, and it means the deleveraging must be funded by the offering rather than by the business.
• Return on equity 6.9%, return on invested capital 5.0%, return on assets 2.5%. These are low, and they are the honest measure of what this capital base produces.

5. The sponsor overhang — the largest non-financial fact in the file

The insider block records three Form 4 entries filed 2026-06-01 for transactions dated 2026-05-28 by BCP 8 Holdings Mozart Manager L.L.C., described as a ten-percent owner, all indirect dispositions of Class A common stock:

Three observations, in order of importance.

First, the remaining position is very large. Roughly 99.8 million shares against a diluted count of ~825M is approximately 12% of the company — held by a single financial owner with an evident disposition programme. That is a supply overhang of a size and character that materially affects the price path, and it is unquantifiable in timing.

Second, the sale price is 9.7% BELOW today's price. $36.5375 against $40.47. A financial sponsor with full information sold $803M at a price the market has since exceeded. This is not a signal about value — sponsors sell to distribute, not to time — but it does establish that a very large, well-informed holder was a willing seller within 10% of the current level.

Third, and worth stating plainly: there are no other insider transactions in the file at all. No officer purchases, no director purchases, no open-market buying by anyone. In a stock 19.0% below its high, seven months after listing, that absence is notable.

6. Valuation — what is priced at $40.47

At $40.47 (market cap $34.22B, net debt $10,622M, EV ~$44.84B):

Trailing GAAP EPS is $1.177 ($0.42 + $0.41 + $0.22 + $0.16), giving 34.3x. No trailing adjusted multiple is computed, because the June 2025 quarter has no adjusted figure (§1).

Note the FY29/FY30 EPS coverage — three analysts each. Those years are excluded from the valuation, which is built on FY27E where coverage is 18 on revenue and 15 on EPS.

6a. What today's price assumes (the inversion)

Reverse-engineering $40.47 into falsifiable claims. Consensus-derived arithmetic, labelled as such.

• Revenue compounds at ~8% annually through FY28, reaching $36,052M. Consensus (16-18 analysts). At 13.2x FY27E EV/EBITDA the price is broadly consistent. Falsifiable quarterly. The March 2026 quarter delivered +10.7%, ahead of the requirement.
• EBITDA margin holds at roughly 10.1-10.2% of revenue (FY26E $3,148M on $31,083M; FY27E $3,399M on $33,561M). This is where the price and the recent evidence diverge most sharply. The trailing EBITDA margin is 9.4% and the March quarter's gross margin fell 220 basis points. Consensus assumes margin stability that the last two quarters have not delivered.
• Gross margin recovers toward ~24-25% from the March quarter's 22.6%. Not stated anywhere in the estimates, but arithmetically required for the EBITDA path above. This is the most fragile assumption in the price, and it is the specific thing to test on 2026-08-05.
• Net leverage falls from ~3.4x toward ~2.9x by FY28, with interest expense continuing to decline from the current $165M per quarter. The deleveraging is real and is roughly a quarter of the modelled EPS growth. Falsifiable quarterly and currently on track.
• The sponsor's remaining ~99.8 million shares are absorbed without materially depressing the price. Not an estimate line; an unpriced supply assumption. The 2026-05-28 sale at $36.5375 is the only observation available and it clears 9.7% below spot.
• $8,079M of goodwill is not impaired. 23.6% of market capitalisation, on a business whose tangible book value per share is negative $2.98.

6b. The return bridge (why the multiple moves)

Expected return over a two-year horizon: EBITDA growth (+8% annually, consensus) + deleveraging transfer + multiple drift + shareholder yield (zero — no dividend, no buyback).

The deleveraging transfer is the distinctive feature of this bridge and deserves explicit treatment. At an enterprise value of $44.84B and net debt of $10.62B, equity is 76.3% of the capital structure. Each $1 of debt repaid transfers $1 of enterprise value to equity holders at a constant EV/EBITDA multiple. With free cash flow of roughly $1.3B annually, that is potentially ~$1.30 per share per year of value transfer, or 3.2% — if the cash goes to debt rather than to working capital. The three-year record of flat free cash flow against 22.4% revenue growth is the reason to be sceptical that it will.

Our base case assumes modest multiple COMPRESSION: we apply 13.0x FY27E EBITDA against the 13.2x the market pays for FY27E today. The justification is that a business with a decelerating top line (+9.3% to +7.4% on consensus), a compressing gross margin, 3.4x leverage and 2.6x interest coverage is not a candidate for re-rating, and that 14.2x FY26E is already a full multiple for a distributor.

So the base-case return of roughly +1% is: ~8% of EBITDA growth plus a ~3% deleveraging transfer, almost entirely offset by a modest de-rate and by the fact that the starting price already reflects both. There is no yield leg (no dividend, no buyback). The bull case at $51 explicitly requires multiple EXPANSION to 15.5x — which needs gross margin to recover and the sponsor overhang to clear. That is the fragile leg and it requires two independent things to go right.

6c. Variant perception (where we differ, what would surprise)

• We differ from the 12-Buy consensus on the gross-margin trajectory. The FY26-28 EBITDA path requires margin stability; the last two reported quarters delivered 24.6% then 22.6%, against 24.8% a year earlier. We think consensus is modelling through a compression it has not yet explained, and note that the sell-side rating distribution (12 Buy, 2 Hold, 0 Sell) is the pattern typical of underwriter-affiliated coverage seven months after a listing rather than of independent assessment. Negative surprise, watchable 2026-08-05: gross margin at or below ~23%, a second consecutive compressed quarter.
• We think the interest-expense reduction is genuinely underappreciated and is the strongest argument for the name. From $233M (June 2025) to $165M (March 2026) is $272M annualised on $964M of trailing net income. Almost no commentary treats a mechanical, already-achieved interest saving as an earnings driver, but it is one and it is durable. Positive surprise, watchable quarterly: interest expense below ~$150M, implying further paydown.
• We think the adjusted-versus-GAAP gap needs scrutiny that the coverage is not applying. March quarter adjusted EPS of $0.33 against GAAP of $0.16 — roughly half the adjusted figure is add-back, undisclosed in composition, on a company seven months public. Negative surprise, watchable: the gap widening further, or a subsequent disclosure revealing recurring costs treated as non-recurring.
• The under-priced structural risk is the disclosure posture itself. A $29.1 billion-revenue public company reporting no product segment revenue and no geographic segment revenue is unusual. It means neither we nor anyone else can attribute the margin compression, which materially raises the required discount. Watchable: whether segment disclosure appears in subsequent filings — its appearance would itself justify a higher multiple.
• Where we have NO edge: on the pace and pricing of the sponsor's remaining ~99.8 million shares. That is a supply variable, not an analytical one.

Synthos fair values

• Bear ~$30 — 10.5x FY27E EBITDA ($3,398.6M) = EV $35.69B less net debt $10,622M = $25.07B ÷ 825M shares = $30.39. Assumes gross-margin compression proves structural, EBITDA margin settles near 9%, and the market applies a levered-distributor multiple while the sponsor distributes. −26%.
• Base ~$41 — 13.0x FY27E EBITDA ($3,398.6M) = EV $44.19B less $10,622M = $33.57B ÷ 825M = $40.69. Assumes ~8% revenue growth, gross margin stabilising near 24%, and continued deleveraging at a broadly unchanged multiple. +1%.
• Bull ~$51 — 15.5x FY27E EBITDA = EV $52.68B less $10,622M = $42.06B ÷ 825M = $50.98, which lands almost exactly on the $51.14 street consensus. Assumes gross margin recovers toward 25-26%, net leverage falls below 3.0x, and the overhang clears. +26%.

Base sits ~1% above spot — effectively at fair value — with a −26% bear and a +26% bull. A perfectly symmetric distribution around the current price, with a binary event tomorrow. That is a Watch by construction.

7. Technicals — insufficient history to read

• Price $40.47, +3.0% on the day, −19.0% from the $49.99 fifty-two-week high; fifty-two-week low $33.19, so the stock sits 21.9% above its low.
• +6.4% above a 50-day average ($38.05).
• There is NO 200-day average — tech.sma200 is null — and no twelve-month return — tech.ret_12m is null. The company listed on 2025-12-17, under eight months ago. The primary-trend indicator that anchors every other technical read in this batch simply does not exist here.
• RSI 57.0, MACD +0.22. Mildly constructive.
• Measurable relative performance is negative on both available horizons: −9.6% over three months against +5.1% for the S&P; −8.4% over six months against +9.5%. Medline has underperformed by 15 and 18 points respectively.
• The reported beta of −0.41 is unusable (§1).
• Read: there is not enough history to draw a technical conclusion, and that is itself the conclusion. A name without a 200-day average, without a twelve-month return and without a usable beta cannot be sized on any risk framework that depends on them. That argues for waiting, not for a smaller position.

8. Knowledge base — zero claims

A search of 51,928 knowledge-base entries for "MDLN" and "Medline" returned zero matches of any kind. Not a tangential mention, not a name collision, not a sector claim naming the company.

kb_claim_count: 0. kb_breadth: 0.

This dive is fundamentals- and quant-driven only — an accepted and precedented outcome, and never a reason to manufacture conviction. Combined with the empty segment disclosure (§1) and the absence of a 200-day average, it means Medline is the least-triangulated name in this batch alongside Sunbelt Rentals: no expert view, no segment detail, no primary-trend indicator, no usable beta, and under eight months of price history. That is not an argument that the company is bad. It is an argument that the required discount is larger than the arithmetic alone suggests, and it is a substantial part of why the verdict is Watch when the base case is at spot rather than below it.

9. Moat and competitive position

Medline's advantage is vertical integration at scale: it manufactures and sources its own branded products and runs the distribution network that delivers them, so it captures both the product margin and the logistics margin on the same shipment. At $29.1B of revenue with 45,000 employees it is one of a small number of participants with national scale in the United States, and hospital supply relationships are sticky — they involve contracted formularies, integrated ordering systems and clinician familiarity.

The evidence the moat prices: revenue growth of 8-11% annually for four consecutive years at a $21-29B scale, which requires taking share.

The evidence the moat is under pressure: gross margin fell 220 basis points year-over-year in the most recent quarter, and operating margin fell 316 basis points (8.90% to 5.74%). A business with genuine pricing power does not surrender 220 basis points of gross margin while growing revenue 10.7%. The most likely readings are input-cost inflation on globally sourced product, or procurement pressure from consolidating health systems — and the empty segment disclosure prevents distinguishing them.

Moat: real in scale and integration, currently not visible in the margin. That combination — a structural advantage that is not showing up in the numbers — is exactly the situation in which a full multiple is dangerous.

10. Capital allocation

• The dominant act of FY25 was deleveraging: net debt down $6,027M, funded by the offering. The cash-flow statement's $2,003M of "common stock repurchased" is IPO reorganisation mechanics rather than an ordinary buyback, and should not be read as capital return.
• No dividend (dividendYieldTTM: 0, lastDividend: 0).
• Capital expenditure $447M (FY25), 1.6% of revenue, up from $364M (FY24) and $285M (FY23) — a rising but still modest reinvestment rate for a manufacturer-distributor.
• Acquisitions: $1,126M in FY24, essentially nil in FY25 and FY23. Goodwill has been broadly flat at $7.5-8.1B for three years, so this is not a serial-acquisition story.
• Free cash flow flat at $1,297M-$1,405M for three years while revenue grew 22.4% — the working-capital drag documented in §4. This is the single most important allocation constraint: the business does not currently self-fund its own deleveraging.

The forward allocation question: with 3.4x leverage, 2.6x interest coverage and no dividend, essentially all free cash flow should go to debt reduction, and each turn of deleveraging transfers roughly $3.4B of enterprise value to equity. That is the mechanism the bull case depends on, and its constraint is whether free cash flow can grow beyond the $1.3B it has been stuck at.

11. Verdict, kill-criteria and flip conditions

Watch.

There is a genuine engine here and it should be credited: net debt down $6,027M, quarterly interest expense down 29% from $233M to $165M — roughly $272M a year of pre-tax income arriving mechanically on a business earning $964M — alongside consistent revenue growth of 8-11% at a $29 billion scale, a defensible vertically integrated position in a demographically supported category, and a forecast EBITDA series that (unusually for this batch) passes internal validation. The street's $51.14 target is 26.4% above spot.

We are not initiating, for four specific reasons.

One: there is no margin of safety. Base case $41 against a $40.47 spot, with a −26% bear and a +26% bull. Perfectly symmetric around the current price, with earnings tomorrow.

Two: gross margin is compressing and nobody can attribute it. 24.8% (March 2025) to 22.6% (March 2026) — 220 basis points, roughly $640M of annual gross profit, on a business whose entire trailing net income is $964M and whose operating margin is 5.7%. seg_prod and seg_geo are both entirely empty, so the cause cannot be determined from this data. Meanwhile GAAP net income fell 60% year-over-year in that quarter while the adjusted figure beat — and adjusted EPS of $0.33 against GAAP EPS of $0.16 means roughly half the adjusted number is undisclosed add-back.

Three: a very large, well-informed seller is still there. A ten-percent holder sold 21,969,126 shares at $36.5375 on 2026-05-28 — roughly $803M, 9.7% below today's price — and retains approximately 99.8 million shares, about 12% of the company. There are no offsetting insider purchases anywhere in the file.

Four: the security cannot be risk-assessed on standard measures. No 200-day average, no twelve-month return, a beta of negative 0.41, under eight months of trading, and zero knowledge-base coverage across 51,928 entries.

Position: none.

Pre-registered conditions to move from Watch to a starter position:

1. Two consecutive quarters of gross margin at or above ~24% — the necessary condition. This is testable tomorrow and again in November.

2. Clarity on the sponsor's remaining ~99.8 million shares — either a completed distribution or a stated lock-up, removing the unquantifiable supply overhang.

3. A price below ~$34 — approaching the fifty-two-week low and the $36.54 level at which the sponsor transacted, at roughly 11.5x FY27E EBITDA, where the base case would pay ~20% instead of ~1%.

4. Only then, and only at 1-2%, pending a usable 200-day average and beta.

Pre-registered KILL / do-not-buy criteria:

• A third consecutive quarter of gross margin below ~23.5% — this would confirm structural rather than transitory compression and would invalidate the entire FY26-28 EBITDA path the price rests on.
• Net leverage rising above ~4.0x — with 2.59x interest coverage, the thinnest in this batch, there is limited tolerance.
• Any goodwill impairment — $8,079M is 23.6% of market capitalisation and tangible book value per share is negative $2.98.
• Free cash flow falling below ~$1.0B — it has been flat at $1.3-1.4B for three years while revenue grew 22.4%, and the deleveraging case depends on it growing.
• The adjusted-to-GAAP gap widening beyond the current ~50% of adjusted EPS, or any disclosure revealing recurring costs treated as non-recurring.

Pre-registered FLIP TO BUY:

• Gross margin recovering to ~25%+ for two consecutive quarters with revenue growth intact — this is the single decisive test, and it would simultaneously validate the EBITDA path and the moat.
• A price below ~$34 with the deleveraging trajectory intact — the same business at 11.5x FY27E EBITDA, where the interest-expense engine is being handed over free.
• Segment disclosure appearing in subsequent filings. A $29B business publishing product and geographic revenue would materially reduce the opacity discount we are applying, and would allow the margin question to be answered rather than inferred.
• Interest expense below ~$150M per quarter with net leverage under 3.0x — the deleveraging engine running ahead of schedule.

Where MDLN fits in the Synthos Framework Portfolio. The healthcare-distribution sleeve, as a deleveraging-and-scale holding — target 1-2% at the right price, currently 0%. It is genuinely complementary rather than redundant to the diagnostics names in this batch: Natera and Illumina sell high-margin science (65% and 67% gross margins) into research and clinical markets, while Medline sells 24%-margin physical consumables into hospital procurement. Different demand driver, different margin structure, different cycle — but also a reminder that scale alone does not confer pricing power. Logged as a tracked Synthos call (Watch, no position; primary gate is two quarters of gross margin ≥24%) as of 2026-08-04 at $40.47.

Single biggest risk: 220 basis points of year-over-year gross-margin compression on a 5.7% operating margin, with no segment data to attribute it. On $29.1 billion of revenue that is roughly $640 million of gross profit — more than the entire $964 million of trailing net income — and both seg_prod and seg_geo are empty, so neither we nor anyone reading this file can tell whether it is tariffs, input costs, procurement pressure or mix.

Most fragile assumption in the price: that EBITDA margin holds at roughly 10.1-10.2% of revenue through FY28. That is what the consensus EBITDA path of $3,148M, $3,399M and $3,651M requires; the trailing figure is 9.4% and the most recent quarter's gross margin was the lowest in the file. The interest-expense engine is real and mechanical, but it is currently being consumed entirely by operating deterioration and then some — operating income fell from $629M to $422M over three quarters while interest expense fell $68M.

Provenance and disclosures

• Traceability: ZERO tagged knowledge-base claims. A search across 51,928 entries for "MDLN" and "Medline" returned no matches of any kind — not a tangential mention, not a name collision. kb_claim_count: 0, kb_breadth: 0. No tracked voice has expressed a view on this company. This dive is fundamentals- and quant-driven only — an accepted and precedented outcome, and never a reason to manufacture conviction.
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates, prices, technicals and knowledge-base claims 2026-08-04. All market data drawn exclusively from scripts/deepdive/vti_data/MDLN_data.json. Company listed 2025-12-17; under eight months of public trading history.
• Vendor data rejected (see §1): (a) inc_a FY2025 EBITDA of $1,952M against operating income of $2,212M — arithmetically impossible; contradicted by the quarterly sum ($2,849M) and by FY2024's $3,532M. (b) inc_q Q4'25 EBITDA of $382M against operating income of $425M — the same impossibility at quarterly level. (c) The trailing capital-expenditure series — capexToRevenueTTM of 0.017% and capexToDepreciationTTM of 0.0075 imply ~$5M of trailing capex against $447M actually reported in FY25; consequently priceToFreeCashFlowRatioTTM (22.4x), freeCashFlowYieldTTM (4.46%), freeCashFlowPerShareTTM ($1.862) and evToFreeCashFlowTTM (29.3x) are all overstated and discarded. Our recomputation: FY25 operating cash flow $1,744M less capex $447M = free cash flow $1,297M, a 3.79% yield. (d) profile.beta of −0.41062886 — a regression artifact of under eight months of history, corroborated by null sma200 and null ret_12m; unusable, and no risk statement relies on it.
• Vendor data flagged: cf_a reports stock-based compensation of $0 in every year including FY2025 — implausible for a newly public company with 45,000 employees, and it means the $1,297M free-cash-flow figure may be flattered by an unsized non-cash charge. bal_a FY2025 introduces $8,549M of minority interest where FY2024 and FY2023 reported zero, reflecting the IPO reorganisation — FY25 equity is not comparable with prior years and price-to-book across the transition is meaningless. Share count is inconsistent: 825.0M diluted in inc_q, ~845.6M implied by the quote's market capitalisation, ~819.0M implied by km_ttm.revenuePerShareTTM; we use 825M and flag the 2.5% spread.
• SEVERE data gaps stated, not papered over: seg_prod and seg_geo are BOTH entirely empty for a $29.1 billion-revenue business, despite the profile naming two divisions (Medline Brand, Supply Chain Solutions) and three product categories. This means the 220 basis-point gross-margin compression — the central operating question of this dive — cannot be attributed to product, geography, or mix from this data, and no claim in this dive rests on a segment split. earn_cal contains only four rows, one without an estimate, so no trailing adjusted-EPS multiple is computed anywhere in this dive. tech.sma200 and tech.ret_12m are both null. FY29E and FY30E EPS rest on three analysts each and are excluded from valuation.
• Vendor data checked and found SOUND — worth noting: unlike NTRA, ILMN and TWLO in this same batch, Medline's forecast EBITDA series passes an internal consistency check — FY26E EBITDA of $3,148M sits above FY26E EBIT of $2,001M by $1,146M of implied depreciation, both positive and close to FY24's actual $3,532M. The FY26-28 EBITDA series is the basis of the valuation. The income statement is also clean: FY25 quarterly revenue sums to $28,432M, matching the annual line exactly.
• Insider disclosure (§5): three Form 4 entries filed 2026-06-01 for transactions dated 2026-05-28 record BCP 8 Holdings Mozart Manager L.L.C., a ten-percent owner, disposing of 21,969,126 shares at $36.5375 (roughly $803M) — 9.7% below the current $40.47 — and retaining approximately 99,788,817 shares, about 12% of the diluted count. No offsetting insider purchases appear anywhere in the file.
• Fair-value method: scenario multiples applied to consensus FY27E EBITDA ($3,398.6M, 18 revenue and 15 EPS contributors), less net debt of $10,622M, divided by 825M shares. Bear 10.5x, base 13.0x, bull 15.5x (which lands on the $51.14 street consensus). Stated arithmetic only — no discounted-cash-flow model was built.
• Timing caveat: written the day before the Q2'26 print (2026-08-05). The recommendation is explicitly no position, and the single most important thing to read in that print is gross margin, not the adjusted-EPS headline — the March quarter delivered an adjusted beat while GAAP net income fell 60% year-over-year.
• Not investment advice. Independent research, educational and informational only, never personalised.
• Version: 2026-08-04-full.